Insider Trading activities at Amylin Pharmaceuticals Inc (AMLN)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Amylin Pharmaceuticals Inc (AMLN) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Amylin Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 881464.

Total stock buying since 2010: $0.
Total stock sales since 2010: $2,098,599.
Total stock option exercises since 2010: $1,951,883.

▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Amylin Pharmaceuticals Inc* (*AMLN*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2012	0	$0	85,590	$1,493,677	85,293	$884,925
2011	0	$0	44,420	$587,289	94,250	$686,333
2010	0	$0	1,314	$17,633	35,000	$380,625

Table 2. Monthly summary of insider trading at *Amylin Pharmaceuticals Inc* (*AMLN*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2012-07	0	$0	0	$0	56,300	$672,785
2012-05	0	$0	0	$0	18,000	$167,040
2012-03	0	$0	20,616	$405,007	5,000	$45,100
2012-02	0	$0	63,142	$1,067,438	0	$0
2012-01	0	$0	1,832	$21,232	5,993	$0
2011-10	0	$0	15,000	$131,220	62,500	$358,125
2011-05	0	$0	0	$0	3,000	$33,090
2011-03	0	$0	13,750	$206,525	13,750	$128,246
2011-02	0	$0	12,500	$202,035	12,500	$139,060
2011-01	0	$0	3,170	$47,509	2,500	$27,812
2010-11	0	$0	1,314	$17,633	25,000	$278,125
2010-05	0	$0	0	$0	10,000	$102,500

Table 3. Detailed insider trading at *Amylin Pharmaceuticals Inc* (*AMLN*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2012-07-26	Bradbury Daniel (President & Chief Executive Of)	Option Ex	36,000	11.95	430,200
2012-07-26	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	20,300	11.95	242,585
2012-05-11	Skyler Jay S (Director)	Option Ex	18,000	9.28	167,040
2012-03-29	Rowland Lloyd A (VP, Chief Compliance Officer)	Sale	3,000	25.00	75,000
2012-03-28	Rowland Lloyd A (VP, Chief Compliance Officer)	Sale	5,000	22.83	114,149
2012-03-28	Rowland Lloyd A (VP, Chief Compliance Officer)	Option Ex	5,000	9.02	45,100
2012-03-01	Weyer Christian (SVP, Research & Development)	Sale	1,231	17.11	21,062
2012-03-01	Mihalik Vincent P (SVP, Chief Commercial Officer)	Sale	1,231	17.11	21,062
2012-03-01	Lloyd Marcea Bland (SVP, Chief Administrative Officer)	Sale	1,846	17.11	31,585
2012-03-01	Gergen Mark J (SVP, Corporate Development)	Sale	1,846	17.11	31,585
2012-03-01	Leonhardt Harry J (SVP, Legal, Compliance and Cor)	Sale	1,231	17.11	21,062
2012-03-01	Bradbury Daniel (President & Chief Executive Of)	Sale	1,539	17.11	26,332
2012-03-01	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	1,846	17.11	31,585
2012-03-01	Foletta Mark G (SVP, Chief Financial Officer)	Sale	1,846	17.11	31,585
2012-02-23	Weyer Christian (SVP, Research & Development)	Sale	2,519	17.03	42,898
2012-02-23	Mihalik Vincent P (SVP, Chief Commercial Officer)	Sale	7,518	17.03	128,031
2012-02-23	Lloyd Marcea Bland (SVP, Chief Administrative Officer)	Sale	7,518	17.03	128,031
2012-02-23	Marshall Paul (SVP, Operations)	Sale	5,638	17.03	96,015
2012-02-23	Gergen Mark J (SVP, Corporate Development)	Sale	7,518	17.03	128,031
2012-02-23	Leonhardt Harry J (SVP, Legal, Compliance and Cor)	Sale	2,180	17.03	37,125
2012-02-23	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	5,638	17.03	96,015
2012-02-23	Foletta Mark G (SVP, Chief Financial Officer)	Sale	5,638	17.03	96,015
2012-02-08	Weyer Christian (SVP, Research & Development)	Sale	3,843	16.61	63,851
2012-02-08	Mihalik Vincent P (SVP, Chief Commercial Officer)	Sale	3,842	16.62	63,838
2012-02-08	Lloyd Marcea Bland (SVP, Chief Administrative Officer)	Sale	5,653	16.62	93,930
2012-02-08	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	5,637	16.61	93,658
2012-01-17	Denner Alexander J (Director)	Sale	1,832	11.59	21,232
2012-01-17	Denner Alexander J (Director)	Option Ex	5,993	.00	0
2011-10-04	Bradbury Daniel (President & Chief Executive Of)	Option Ex	45,000	5.73	257,850
2011-10-04	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	2,500	5.73	14,325
2011-10-03	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	15,000	8.75	131,220
2011-10-03	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	15,000	5.73	85,950
2011-05-24	Skyler Jay S (Director)	Option Ex	3,000	11.03	33,090
2011-03-01	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	13,750	15.02	206,525
2011-03-01	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	13,750	9.33	128,246
2011-02-01	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	7,500	16.16	121,221
2011-02-01	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	7,500	11.12	83,436
2011-01-18	Kolterman Orville G (SVP, Chief Medical Officer)	Sale	2,500	15.00	37,500
2011-01-18	Kolterman Orville G (SVP, Chief Medical Officer)	Option Ex	2,500	11.12	27,812
2011-01-18	Gavin James R Iii (Director)	Sale	670	14.94	10,009
2010-11-22	Bradbury Daniel (President & Chief Executive Of)	Option Ex	25,000	11.12	278,125
2010-11-19	Weyer Christian (SVP, Research & Development)	Sale	1,314	13.42	17,633
2010-05-28	Skyler Jay S (Director)	Option Ex	10,000	10.25	102,500

Insider trading activities including stock purchases, stock sales, and option exercises of AMLN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Amylin Pharmaceuticals Inc (symbol AMLN, CIK number 881464) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month